ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$11.13
0.13 (1.18%)
▲
5d:
+10.53%
30d:
+14.62%
90d:
+29.42%
BUY
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 19, 2026
8d
Smart Money Accumulation
ZVRA is down 7.8% this week, but smart money is accumulating calls. Top strike: $11 2026-06-18 with 12 OI. Call ratio: 100% View Scanner →
Strength: 8.9/10
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called ZVRA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 14.2% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 14.2% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$34.43
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$21.38
47.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $11.13, which is considered extended relative to its 30-day fair value range of $9.48 to $10.63. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.0) compared to its historical average (11.1). Remarkably, the market is currently pricing in an annual earnings decline of 14.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $9.47, while resistance sits at $11.60.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $22.78 (+104.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $9.47, while resistance sits at $11.60.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $22.78 (+104.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.48 -
$10.63
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 104.7% below Wall St target ($22.78)
Trading Range Analysis
30-Day Trading Range
$9.48 -
$10.63
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.48
Resistance Level
$11.60
Current Trend
Strong Uptrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.99
Wall Street Target
$22.78
(+104.7%)
Revenue Growth (YoY)
183.4%
Profit Margin
78.2%
Valuation Discount vs History
-14.2% cheaper
PE vs Historical
7.0 vs 11.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.2%
(market-implied from PE analysis)
1-Year Target
$10.02
(-10%)
2-Year Target
$9.02
(-19%)
3-Year Target
$8.11
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7→11)
$12.89
(+16%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 220.4%)
$117.95
(+960%)
Base:
(SPY PE: 7.0, Growth: 220.4%)
$37.56
(+238%)
Bear:
(PE: 5.9, Growth: 220.4%)
$31.93
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 8.15 | Current EPS (TTM): $1.35
Bull Case
$14.28
(+28%)
Analyst growth 18.0%, PE expands to 9.0
Base Case
$12.98
(+17%)
Market implied 18.0%, PE stable at 8.2
Bear Case
$7.48
(-33%)
Severe decline -20.0%, PE contracts to 6.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.0 to 11.1
Stabilization Target:
$17.68
(+58.9%)
PE Expansion Potential:
+58.9%
Share & Embed Analysis
Last updated: May 10, 2026 3:51 PM ET
Data refreshes hourly during market hours. Next update: 4:51 PM
Data refreshes hourly during market hours. Next update: 4:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua Schafer
SELL
10500 shares
2026-02-03
Timothy J Sangiovanni
SELL
3000 shares
2026-02-03
Neil F Mcfarlane
SELL
91000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 60 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 54 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 60 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 52 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 57 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
